Over the past few years, loss of patent protection for blockbuster monoclonal antibody (mAb)
drugs has caused a significant shift in the pharmaceutical industry towards the development …

Psoriasis is a chronic autoimmune inflammatory disease characterized by erroneous
metabolism of keratinocytes. The development of psoriasis is closely related to abnormal …

Biosimilars are poised to reduce prices and increase patient access to expensive, but highly
effective biologic products. However, questions still remain about the degree of similarity …

Membrane proteins and associated complexes currently comprise the majority of therapeutic
targets and remain among the most challenging classes of proteins for analytical …

FDA-approved anti-TNFα biopharmaceuticals are successful in treating a range of
autoimmune diseases. However, not all anti-TNFα products are identical in their patient …

Humira®(adalimumab) by AbbVie has been the top-selling biologic drug product for the last
few years–reaching nearly $20 billion in annual sales in 2018. Upon the October 2018 …

Purpose ABP 710 has been developed as a biosimilar to infliximab reference product (RP).
The objective of this study was to assess analytical similarity (structural and functional) …

Abstract. The development of monoclonal antibody (mAb) biosimilars is a complex process.
The key to their successful development and commercialization is an in-depth …

Background: Since the late '90s, infliximab (Remicade®) is being used successfully to treat
patients with several non-infectious immune mediated inflammatory diseases (IMIDs). In …

Meyer and colleagues reported a large and well-conducted cohort study that demonstrates
that the effectiveness of the biosimilar CT-P13 is equivalent to that of infliximab in infliximab …